Drugs / TRCN-1023
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07674667 | Jul 2026 → Sep 2027 expected | amyotrophic lateral sclerosis | Trace Neuroscience, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | Trace Neuroscience, Inc. | Trace Neuroscience Initiates Global Clinical Development Program for TRCN-1023, an Antisense Oligonucleotide Designed to Restore UNC13A Function for the Treatment of ALS traceneuro.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRCN-1023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07674667 ↗ |
| Action | Restore | “designed to restore the function of a protein called UNC13A” NCT07674667 ↗ |
| Modality | Antisense oligonucleotide | “Antisense oligonucleotide (ASO) administered by intrathecal injection” NCT07674667 ↗ |
| Route | Intrathecal | “intrathecal injection” NCT07674667 ↗ |